WhaleCreep
Home › Funds › Caligan Partners LP › Q1 2025

Caligan Partners LP 13F holdings, Q1 2025

Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →

Caligan Partners LP disclosed 16 US equity positions worth $479.2m in its Q1 2025 13F filing. The largest position was LQDA at 25.0% of the reported book, followed by VRNA and EXEL. Against the Q4 2024 filing, it opened 3 new positions, added to 8 and reduced 0 among the top 16 holdings.

← Q4 2024 · Q2 2025 →

What did Caligan Partners LP own in Q1 2025? Top 16 positions

#StockSectorWeightValueSharesΔ sharesvs Q4 2024
1 LQDA LIQUIDIA CORPORATION Healthcare 25.0%$119.7m8,118,592 0% held
2 VRNA VERONA PHARMA PLC 19.0%$91.2m1,436,878 0% held
3 EXEL EXELIXIS INC Healthcare 11.8%$56.3m1,525,730 0% held
4 MLYS MINERALYS THERAPEUTICS INC Healthcare 7.1%$34.1m2,149,667 113% added
5 EOLS EVOLUS INC Healthcare 6.9%$32.9m2,731,154 1% added
6 SG7 SAGE THERAPEUTICS INC 5.1%$24.3m3,052,538 0% held
7 BCRX BIOCRYST PHARMACEUTICALS INC Healthcare 4.9%$23.3m3,107,669 4% added
8 ANIK ANIKA THERAPEUTICS INC Healthcare 4.5%$21.6m1,435,130 0% held
9 AGIO AGIOS PHARMACEUTICALS INC Healthcare 4.3%$20.5m701,280 12% added
10 RVMD REVOLUTION MEDICINES INC Healthcare 3.4%$16.4m465,000 – new
11 MERUS N V 3.3%$15.9m376,954 48% added
12 YMABUSD Y-MABS THERAPEUTICS INC 2.2%$10.4m2,342,609 33% added
13 ABVX ABIVAX SA 1.7%$7.9m1,269,119 69% added
14 VRCA VERRICA PHARMACEUTICALS INC 0.8%$4.0m8,992,954 21% added
15 RZLT REZOLUTE INC 0.1%$409.8k141,309 – new
16 TYRA TYRA BIOSCIENCES INC Healthcare 0.0%$232.5k25,000 – new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.